BFRG BullFrog AI Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1829247 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY4.1%
TTM EPS YoY40.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-184.0%
ROA-152.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets12.4%
Debt / equity0.00x
Current ratio7.75x
Interest coverage-1,202.80x
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $63,578 | $215,385 | — | $0 | $83,413 | $33,257 | — | — |
| Cost of revenue | $53,542 | $108,486 | — | $0 | $68,043 | $26,735 | — | — |
| Gross profit | $10,036 | $106,899 | — | $0 | $15,370 | $6,522 | — | — |
| R&D expense | $439,240 | $339,456 | $434,819 | $397,189 | $345,992 | $480,297 | $576,260 | $590,856 |
| SG&A expense | $1.62M | $1.19M | $1.18M | $1.10M | $1.24M | $995,898 | $1.48M | $1.18M |
| Operating income | -$2.05M | -$1.42M | -$1.61M | -$1.50M | -$1.57M | -$1.47M | -$2.06M | -$1.77M |
| Interest expense | $1,497 | $2,373 | $982 | $622 | $1,543 | $2,449 | $1,015 | $2,008 |
| Net income | -$2.01M | -$1.37M | -$1.59M | -$1.48M | -$1.55M | -$1.45M | -$2.02M | -$1.71M |
| EBITDA | -$2.05M | -$1.42M | -$1.61M | -$1.50M | -$1.57M | -$1.47M | -$2.06M | -$1.77M |
| EPS (basic) | -0.11 | -0.07 | -0.12 | — | -0.15 | -0.15 | -0.21 | — |
| EPS (diluted) | -0.11 | -0.07 | -0.12 | — | -0.15 | -0.15 | -0.21 | — |
| Weighted avg. shares (diluted) | 18.87M | 18.81M | 12.95M | — | 10.38M | 9.71M | 9.69M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.99M | $6.92M | $5.08M | $2.18M | $2.10M | $2.58M | $3.80M | $5.44M |
| Receivables | $175,000 | — | — | $0 | $58,335 | — | — | — |
| Current assets | $5.57M | $7.47M | $5.32M | $2.58M | $2.54M | $2.70M | $4.08M | $5.55M |
| PP&E, net | $1,231 | $1,662 | $2,094 | $2,525 | $2,956 | $3,387 | $3,818 | $4,250 |
| Total assets | $5.79M | $7.69M | $5.54M | $2.81M | $2.70M | $2.87M | $4.09M | $5.55M |
| Current liabilities | $719,310 | $706,590 | $652,072 | $672,022 | $758,701 | $681,084 | $839,397 | $588,090 |
| Short-term debt | — | — | — | — | $55,606 | $110,291 | $164,070 | — |
| Total liabilities | $719,310 | $706,590 | $652,072 | $672,022 | $758,701 | $681,084 | $839,397 | $588,090 |
| Shareholders' equity | $5.08M | $6.99M | $4.89M | $2.14M | $1.94M | $2.19M | $3.25M | $4.96M |
| Shares outstanding | 18.69M | 18.54M | 18.45M | 11.42M | 10.42M | 9.63M | 9.42M | 9.11M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.88M | -$1.51M | -$1.69M | -$1.18M | -$1.11M | -$1.43M | -$1.80M | -$1.27M |
| Investing cash flow | $0 | — | — | — | $0 | — | — | — |
| Financing cash flow | -$44,622 | $3.35M | $4.59M | $1.38M | $624,249 | $208,680 | $164,070 | $2.47M |
| Depreciation & amortization | $431 | $432 | $431 | $431 | $431 | $432 | $431 | $431 |
| Stock-based compensation | $396 | $1,188 | $126,656 | $154,208 | $145,388 | $177,905 | $300,288 | $214,279 |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.